Baghdadi et al., showed that blocking TIM-4 activity using a mouse TIM-4 antagonist antibody (RMT4-53) in combination with various chemotherapy agents and/or cancer vaccines improved the efficacy of anti-tumor therapies, leading to reduced tumor size and increased survival in mouse models [17, 18]. This evidence concerns the gene TIMD4 and cancer.